(CercleFinance.com) – Amoéba shares climbed more than 21% on the Paris market on Monday following the cancellation of the issue of a new tranche of bonds convertible into shares (OCA), a mode of financing considered as particularly dilutive.
The company – which is at the origin of a biological process capable of eliminating the bacterial risk in water and human wounds – explains that it has terminated its contract for the issuance of bonds convertible into shares concluded with Nice & Green.
This decision will lead it to waive the issue of an eighth optional tranche of 80 OCAs, as initially provided for in the contract.
In order to adapt its financial strategy to its industrial transformation objectives, Amoéba says it has concluded a support contract with the company Redbridge Debt and Treasury Advisory in order to assist it in its search for financing.
This support should take place in two phases, (1) first the search for the optimal financing strategy and (2) support in its financing operations until an envelope of 45 million euros is obtained. .
For the record, Amoéba wants to build a production plant dedicated to biocontrol products, which could produce 40 tonnes of active substance per year, or the equivalent of 100,000 hectares treated.
In order to finance this production site – which should be operational in early 2025 – then start marketing its products in Europe and the United States and continue its activities over the next three years, the company estimates its total financial needs at 45 million euros.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
